

China Economic Perspectives

Tracking Household Income and Consumer Sentiment - UBS Evidence Lab inside

New UBS Evidence Lab China consumer sentiment survey

UBS Evidence Lab conducted a Consumer Sentiment Survey ([Access Dataset](#)) over 12-18 February, collecting answers from 1,000 respondents on questions about their income growth and expectations, consumption spending and future intentions. We compare the results from the latest survey to our [July 2024 Consumer Survey](#) and the [March 2024 post-CNY pulse-check survey](#) to track changes in income expectation and consumer sentiment.

Cautious income expectations weigh on consumption sentiment

The latest survey reveals a softening income growth over the past six months, with a greater proportion of respondents reporting weaker salary growth, softer returns from financial investment or property rentals compared to the March or July 2024 surveys. Looking ahead in the next six months, expectation of future salary income growth held largely stable at a relatively soft level. Confidence of wealth effect through financial investment or property letting weakened, compared to previous surveys. This cautious income outlook casts a shadow over spending intentions. Fewer respondents planned to increase consumption, investments, insurance or savings than March or July 2024.

Notable divergence among city tiers and demographic groups

Amid the generally weak income and consumption outlook, respondents in tier 1 cities fared better than others. They reported better income in the past and expectation for future income growth, which translates to stronger spending intentions than their peers. The youngest cohort (age 18-24) reported the strongest income outlook and spending plans among all age groups. Such difference likely reflects unevenly distributed economic conditions, evident by the notable divergence in property market recovery among different tiers of cities. By products, more respondents plan to increase consumption on sports, F&B, cosmetics, and service activities such as domestic helper services, childcare and elderly care. Meanwhile, spending intention for large ticket items, travelling and luxury cooled from the July 2024 survey.

Boosting consumption listed as top priority, but initial stimulus moderate

Total fiscal stimulus to boost consumption activities remains modest so far. Trade-in subsidies for consumer goods were doubled to RMB300bn (0.2% of GDP) and have been expanded to more home appliances & consumer electronics. The government also vowed to increase social insurance spending and establish childcare/childbirth subsidies, although the annual increase of the former is estimated below RMB100bn and details of the latter remain unknown (see [NPC takeaways](#)). With a top-level action plan announced recently, the government plans to boost income growth for both employees' salary and financial returns, and expand the supply of service consumption (see [more details](#)). We think the government may introduce additional support for labour market and consumption, in the case of more significant external shocks (especially from potentially new higher tariffs after April).

Key uncertainties to watch: property, tariffs, stimulus

The lukewarm income recovery and subdued consumer confidence may continue to weigh on overall household consumption recovery, although modest fiscal stimulus could offer partial offset. Key uncertainties to watch include the property market's uneven recovery, potential additional tariffs, and the scale and timing of any new policy stimulus. Overall, we expect real consumption growth to stay soft at ~4% in 2025, with diverged trends among different city tiers and demographic groups.

Economics

China

Jennifer Zhong

Economist

jennifer-a.zhong@ubs.com

+86-105-832 8324

Tao Wang

Economist

wang.tao@ubs.com

+852-2971 7525

Ning Zhang

Economist

ning.zhang@ubs.com

+852-2971 8135


Amid general subdued consumer sentiment, China rolled out consumption policy stimulus in the fall of 2024, which catalyzed a rebound in related sales. How has consumer sentiment evolved into 2025, and what are consumers' expectations for income and consumption? UBS Evidence Lab conducted a Consumer Sentiment Survey ([> Access Dataset](#)) involving 1,000 respondents after the CNY holiday between 12 and 18 February 2025. We compare the results from this survey to our [July 2024 Consumer Survey](#) ([> Access Dataset](#)) and the [post-CNY pulse-check survey](#) conducted in March 2024 ([> Access Dataset](#)) to track changes in income expectation and consumer sentiment.

General household income growth weakened in the past six months. In the latest survey, 24% of respondents reported rising salary income in the past six months on a net basis (i.e., the percentage of those respondents that reported increased salaries minus those that reported decreased salaries), lower than 35% in the March 2024 or July 2024 survey (where 50% on net basis reported better salary income over the past year). Although the financial market rallied and property sales improved since September 2024, fewer respondents reported increased income from financial investments (net 15% reported an increase) or property letting (net 6% reported an increase), compared with March (26%/20% for investment and rentals, respectively) or July 2024 (47%/45%). For both salary and wealth effect, the weakness in sentiment was due to an increased proportion of respondents that recorded income declines. The results highlight constraints in general spending power. It suggests the financial market recovery and property sales rebound in Q4 2024 have yet to translate into broader household income gains.

Notable divergence among city tiers and demographic groups. Respondents in tier 1 cities seem to be faring better than their peers, with a higher proportion reporting improved salary income and stronger financial returns. In contrast, sentiment on income growth is weaker in lower-tier cities, and across all income sources. In tier 4 cities, for instance, only a net 1% of respondents reported an improvement in property letting income, a sharp decline from 15% in the March 2024 survey.


Demographic differences are also pronounced. The youngest cohort (age 18-24) reported the strongest salary income rebound – 48% reported a salary increase on a net basis, up significantly from 14% in March 2024. This perhaps reflects an improvement in labour market conditions for young people. Meanwhile, sentiment was much softer among age groups 25-34 and 35-44. Such divergence likely reflects asymmetric recoveries in economic growth and the property market, with tier 1 cities benefiting more from policy support and uneven improvements in property prices. [UBS property team](#) has turned more positive on early recovery signals in tier 1 cities and core tier 2 cities.

Figure 1: General household income growth weakened



Source: UBS Evidence Lab ([> Access Dataset](#))

Figure 2: Notable divergence among city tiers




Source: UBS Evidence Lab ([> Access Dataset](#))

Fragile consumer confidence and declining investment intentions in the past six months. Amid softer overall income growth, survey results revealed a more constrained consumption landscape. Only 14% of respondents reported an increase in consumption spending in the past six months on a net basis, halved from 29% in March 2024, and notably lower than 25% in July 2024. In addition, echoing softer returns from financial investments, the bias towards reducing financial investments expanded. A net 12% of respondents said they have decreased investment, from only 1% in March, and in contrast to July 2024 when there was a slight bias towards increasing investment. This reduction in investments was particularly evident among respondents in tier 3 and 4 cities. Similarly, fewer respondents claimed to have increased saving (narrowly defined, bank deposits and cash) or insurance than in the March or July 2024 surveys.


Macro level data showed elevated excess savings and recovering income growth. At the macro level, households continued to accumulate excess savings in the past few years (for more discussion and technical details, please see our [earlier report](#)) in 2024, except a mild temporary release in Q3 2023 and Q3 2024. Official household disposable income growth improved to 5.6% y/y in nominal terms in Q4 2024 from 5% y/y in Q3, leading to recovering consumption growth of 4.5% y/y (in nominal terms) from 3.5% y/y in Q3. That said, both income and consumption growth decelerated a bit in Q4 2024 after scrapping out the impact of base effect (on CAGR basis from 2021). Taken together, survey and macro data suggest income growth stayed soft and consumer sentiment remained fragile.

Figure 3: Fragile consumer confidence and declining investment intentions



Source: UBS Evidence Lab ([Access Dataset](#))

Figure 4: Macro level suggests households accumulated excess savings in the past few years




Source: CEIC, UBS estimates ([Access Dataset](#))

Looking ahead, income and wealth effect remained the most important drivers of future consumption, with policy stimulus gaining momentum modestly.

Among the key drivers for future consumption in 2025, job promotion or stability remains the foremost factor across different surveys (cited by 37% of all respondents in the latest survey), while wealth effect ranked second (cited by 26%). Different from previous surveys, cash subsidies and consumer vouchers (non-cash) both became more important drivers. This shift echoes the government's efforts to boost consumption, particularly through RMB170bn worth of trade-in subsidies in Q424 (more than the planned RMB150bn). The findings also underscore the role of policy boosts in shaping future consumption activities. Indeed, the government doubled the size of trade-in subsidies to RMB300bn in 2025.

Figure 5: The most important drivers for consumption



Source: UBS Evidence Lab ([Access Dataset](#))

What to expect in 2025?


Respondents remain cautious on future salary growth and expect softer wealth effect. On wage growth, the share of respondents that expected their salary to increase in the next six months was largely stable from previous surveys (a net basis of 40% expected an increase, vs 38% in March 2024). This is still short of the full-year expectation in July 2024, where 50% expected their salary to increase on a net basis. On wealth effect front, the gloomy view of past performance may have weighed down respondents' future expectations. Only 21% of respondents (on a net basis) expect their investment return to rise in the future, while just 2% expect an increase in property letting income – both much weaker than March and July 2024 surveys. The weakness is most pronounced in tier 4 cities where only 14% expect investment income to increase (vs 37% in tier 1 and 25% in tier 2/3) and 4% expect property letting income to decline on a net basis (while tier 1-3 expected an increase). Overall, salary and wealth effect expectations remain subdued and divergent across city tiers, which is likely related to respondents' spending intentions.

The government has prioritized “boosting consumption” as the top policy task for 2025, but initial stimulus appears moderate. In 2025, trade-in subsidies for consumer goods have doubled to RMB300bn (0.2% of GDP) and expanded to more home appliances & consumer electronics. The government has also vowed to increase social spending and establish childcare/childbirth subsidies, although the annual increase of the former is estimated below RMB100bn and details of the latter remain unknown (which could possibly exceed RMB100bn or more a year, see [NPC takeaways](#)). With a top-level action plan announced recently (see [more details](#)), the government continued to emphasize lifting income growth, expanding the supply of service consumption by lowering entry barriers and removing related restrictions, implementing the pay-leave scheme, and increasing central government investment in services and skill trainings. As of now, the total size of stimulus package in 2025 looks modest and some policy details still need to be confirmed later. That said, we think the government may introduce additional support for labour market and consumption, in the case of more significant external shocks (especially from potentially new higher tariffs after April).

Lacklustre income expectations likely weigh on consumption outlook. Despite larger subsidies for the consumer trade-in scheme, spending sentiment remains weak amid soft and stable income expectation. A net 10% of respondents plan to increase consumption in the next six months, down from 21% in March 2024, while similar to the July 2024 survey. Unevenly distributed income outlook is reflected in consumption expectations. Respondents in tier 1 cities reported a stronger intention to consume than others, while those in lower-tier cities, in particularly tier 4 cities, were much more reluctant. Whereas in March 2024, respondents in tier 1-3 cities showed similar


spending intention. Meanwhile, intentions to save, invest and buy insurance also declined from March 2024, likely reflecting subdued income outlook.

Figure 6: Largely stable salary income expectations, softer outlook for wealth effect



Source: UBS Evidence Lab ([Access Dataset](#))

Figure 7: Income expectation by income types




Source: UBS Evidence Lab ([Access Dataset](#))

What areas to spend on? Compared to the July 2024 survey, more respondents intend to increase spending on sports (22% of all respondents plan to increase spending on a net basis, vs 15% in July), food and beverages, and cosmetics. Respondents also showed stronger intentions to spend on service activities such as domestic helper services, childcare and elderly care; this highlights the importance of fiscal boosts and policy support. Partly reflecting the expansion of trade-in policy, slightly more respondents than in the July 2024 survey prefer to spend on consumer electronics, even as this category includes computers that were already in scope for subsidies in 2024. Meanwhile, purchase intentions for large-ticket items (property purchases and auto), travelling (outbound and domestic) and luxuries (handbags and jewelry) cooled further from July 2024. Comparison with the March 2024 survey revealed a similar pattern – stronger spending intentions for elderly care, house keeping, helper services; lower spending intentions for dining out, travelling, commuting.

Key uncertainties to watch: property, tariffs, stimulus. We expect the lukewarm income recovery and subdued consumer confidence to weigh on household consumption in the coming quarters. While there are early signs of stabilization in the property market to support consumer sentiment, the current improvement is highly concentrated in tier 1 and core tier 2 cities, while a nationwide recovery may be absent till 2026. If and when the US imposes additional tariffs on China after April, weaker exports later in the year may negatively impact the labour market and constrain household income growth.


Meanwhile, the expansion of trade-in subsidies is likely to provide some support for consumption, especially for products that were not subsidized in 2024. We also expect more details on childcare/childbirth subsidies to be announced soon. That said, the initial boost of fiscal stimulus to support consumption is still modest, and the policy implementation could take some time. Local governments' fiscal capacity to support consumption remains challenging. Furthermore, the stock market rally, if sustained, could offer some support through wealth effect. Overall, we expect real consumption growth to stay soft at ~4% in 2025, with diverged trends among city tiers and demographic groups.

Figure 8: Spending intentions weakened



Source: UBS Evidence Lab ([> Access Dataset](#))

Figure 9: Spending pattern shifts



Source: UBS Evidence Lab ([> Access Dataset](#))

***UBS Evidence Lab** is a sell-side team of experts that work across numerous specialized labs creating insight-ready datasets. The experts turn data into evidence by applying a combination of tools and techniques to harvest, cleanse, and connect billions of data items each month. Since 2014, UBS Research analysts have utilized the expertise of UBS Evidence Lab for insight-ready datasets on companies, sectors, and themes, resulting in the production of thousands of differentiated UBS Research reports. UBS Evidence Lab does not provide investment recommendations or advice but provides insight-ready datasets for further analysis by UBS Research and by clients. All published UBS Evidence Lab content is available via UBS Neo. The amount and type of content available may vary. Please contact your UBS sales representative if you wish to discuss access.

This is the 2nd wave of the China Consumer Sentiment Consumer Survey. UBS Evidence Lab conducted an online survey of 1,000 consumers across China. Fieldwork took place from 12 February to 18 February 2025. The distribution of survey respondents was designed to mirror the population of the country by using census data for age, gender & tier. Participants did not have to meet any qualifying criteria in the survey. This report leverages the following UBS Evidence Lab asset: China consumer sentiment consumer survey. The margin of error for 1,000 respondents is +/- 2.60% at 90% confidence level.

Previous fieldwork date for this survey is:

Wave 1: March 2024

Required Disclosures

This document has been prepared by UBS Securities Asia Limited, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates, including former Credit Suisse AG and its subsidiaries, branches and affiliates are referred to herein as "UBS".

For information on the ways in which UBS manages conflicts and maintains independence of its UBS Global Research product; historical performance information; certain additional disclosures concerning UBS Global Research recommendations; and terms and conditions for certain third party data used in research report, please visit <https://www.ubs.com/disclosures>. Unless otherwise indicated, information and data in this report are based on company disclosures including but not limited to annual, interim, quarterly reports and other company announcements. The figures contained in performance charts refer to the past; past performance is not a reliable indicator of future results. Additional information will be made available upon request. UBS Securities Co. Limited is licensed to conduct securities investment consultancy businesses by the China Securities Regulatory Commission. UBS acts or may act as principal in the debt securities (or in related derivatives) that may be the subject of this report. This recommendation was finalized on: 20 March 2025 04:34 PM GMT. UBS has designated certain UBS Global Research department members as Derivatives Research Analysts where those department members publish research principally on the analysis of the price or market for a derivative, and provide information reasonably sufficient upon which to base a decision to enter into a derivatives transaction. Where Derivatives Research Analysts co-author research reports with Equity Research Analysts or Economists, the Derivatives Research Analyst is responsible for the derivatives investment views, forecasts, and/or recommendations. **Quantitative Research Review:** UBS Global Research publishes a quantitative assessment of its analysts' responses to certain questions about the likelihood of an occurrence of a number of short term factors in a product known as the 'Quantitative Research Review'. Views contained in this assessment on a particular stock reflect only the views on those short term factors which are a different timeframe to the 12-month timeframe reflected in any equity rating set out in this note. For the latest responses, please see the Quantitative Research Review Addendum at the back of this report, where applicable. For previous responses please make reference to (i) previous UBS Global Research reports; and (ii) where no applicable research report was published that month, the Quantitative Research Review which can be found at <https://neo.ubs.com/quantitative>, or contact your UBS sales representative for access to the report or the Quantitative Research Team on qa@ubs.com. A consolidated report which contains all responses is also available and again you should contact your UBS sales representative for details and pricing or the Quantitative Research team on the email above.

Analyst Certification:

Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner, including with respect to UBS, and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

Research analysts contributing to this report who are employed by any non-US affiliate of UBS Securities LLC are not registered/qualified as research analysts with FINRA. Such analysts may not be associated persons of UBS Securities LLC and therefore are not subject to the FINRA restrictions on communications with a subject company, public appearances, and trading securities held by a research analyst account. The name of each affiliate and analyst employed by that affiliate contributing to this report, if any, follows.

UBS AG Hong Kong Branch: Ning Zhang, Tao Wang. **UBS Securities Co. Limited:** Jennifer Zhong.

Unless otherwise indicated, please refer to the Valuation and Risk sections within the body of this report. For a complete set of disclosure statements associated with the companies discussed in this report, including information on valuation and risk, please contact UBS Securities LLC, 1285 Avenue of Americas, New York, NY 10019, USA, Attention: Investment Research.

UBS Global Research Disclaimer

This document has been prepared by UBS Securities Asia Limited, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates, including former Credit Suisse AG and its subsidiaries, branches and affiliates are referred to herein as "UBS".

Any opinions expressed in this document may change without notice and are only current as of the date of publication. Different areas, groups, and personnel within UBS may produce and distribute separate research products independently of each other. For example, research publications from **UBS CIO** are produced by UBS Global Wealth Management. **UBS Global Research** is produced by UBS Investment Bank. Research methodologies and rating systems of each separate research organization may differ, for example, in terms of investment recommendations, investment horizon, model assumptions, and valuation methods. As a consequence, except for certain economic forecasts (for which UBS CIO and UBS Global Research may collaborate), investment recommendations, ratings, price targets, and valuations provided by each of the separate research organizations may be different, or inconsistent. You should refer to each relevant research product for the details as to their methodologies and rating system. Not all clients may have access to all products from every organization. Each research product is subject to the policies and procedures of the organization that produces it.

This document is provided solely to recipients who are expressly authorized by UBS to receive it. If you are not so authorized you must immediately destroy the document.

UBS Global Research is provided to our clients through UBS Neo, and in certain instances, UBS.com and any other system or distribution method specifically identified in one or more communications distributed through UBS Neo or UBS.com (each a system) as an approved means for distributing UBS Global Research. It may also be made available through third party vendors and distributed by UBS and/or third parties via e-mail or alternative electronic means.

All UBS Global Research is available on UBS Neo. Please contact your UBS sales representative if you wish to discuss your access to UBS Neo. Where UBS Global Research refers to "UBS Evidence Lab Inside" or has made use of data provided by UBS Evidence Lab and you would like to access that data please contact your UBS sales representative. UBS Evidence Lab data is available on UBS Neo. The level and types of services provided by UBS Global Research and UBS Evidence Lab to a client may vary depending upon various factors such as a client's individual preferences as to the frequency and manner of receiving communications, a client's risk profile and investment focus and perspective (e.g., market wide, sector specific, long-term, short-term, etc.), the size and scope of the overall client relationship with UBS Global Research and UBS Evidence Lab and legal and regulatory constraints. UBS HOLT is an offering of UBS Global Research. HOLT Lens is a corporate performance platform offering that provides an objective accounting-led framework for comparing and valuing companies and is available to clients of UBS Global Research; for further details and pricing please contact your UBS Sales representative. In particular, HOLT has a variety of warranted prices based on the scenario chosen; please mail UBS Securities LLC, 1285 Avenue of Americas, New York, NY 10019, USA, Attention: Investment Research, if you are interested in the warranted price on a particular company, again subject to commercial considerations. For all other HOLT specific disclaimers, please see <https://www.ubs.com/disclosures>.

When you receive UBS Global Research through a system, your access and/or use of such UBS Global Research is subject to this UBS Global Research Disclaimer and to the UBS Neo Platform Use Agreement (the "Neo Terms") together with any other relevant terms of use governing the applicable System.

When you receive UBS Global Research via a third party vendor, e-mail or other electronic means, you agree that use shall be subject to this UBS Global Research Disclaimer, the Neo Terms and where applicable the UBS Investment Bank terms of business (<https://www.ubs.com/global/en/investment-bank/regulatory.html>) and to UBS's Terms of Use/Disclaimer (<https://www.ubs.com/global/en/legalinfo2/disclaimer.html>). In addition, you consent to UBS processing your personal data and using cookies in accordance with our Privacy Statement (<https://www.ubs.com/global/en/legalinfo2/privacy.html>) and cookie notice (<https://www.ubs.com/global/en/legal/privacy/users.html>).

If you receive UBS Global Research, whether through a System or by any other means, you agree that you shall not copy, revise, amend, create a derivative work, provide to any third party, or in any way commercially exploit any UBS research provided via UBS Global Research or otherwise, and that you shall not extract data from any research or estimates provided to you via UBS Global Research or otherwise, without the prior written consent of UBS.

In certain circumstances (including for example, if you are an academic or a member of the media) you may receive UBS Global Research otherwise than in the capacity of a client of UBS and you understand and agree that (i) the UBS Global Research is provided to you for information purposes only; (ii) for the purposes of receiving it you are not intended to be and will not be treated as a "client" of UBS for any legal or regulatory purpose; (iii) the UBS Global Research must not be relied on or acted upon for any purpose; and (iv) such content is subject to the relevant disclaimers that follow.

This document is for distribution only as may be permitted by law. It is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or would subject UBS to any registration or licensing requirement within such jurisdiction.

This document is a general communication and is educational in nature; it is not an advertisement nor is it a solicitation or an offer to buy or sell any financial instruments or to participate in any particular trading strategy. Nothing in this document constitutes a representation that any investment strategy or recommendation is suitable or appropriate to an investor's individual circumstances or otherwise constitutes a personal recommendation. By providing this document, none of UBS or its representatives has any responsibility or authority to provide or have provided investment advice in a fiduciary capacity or otherwise. Investments involve risks, and investors should exercise prudence and their own judgment in making their investment decisions. None of UBS or its representatives is suggesting that the recipient or any other person take a specific course of action or any action at all. The recipient should carefully read this document in its entirety and not draw inferences or conclusions from the rating alone. By receiving this document, the recipient acknowledges and agrees with the intended purpose described above and further disclaims any expectation or belief that the information constitutes investment advice to the recipient or otherwise purports to meet the investment objectives of the recipient. The financial instruments described in the document may not be eligible for sale in all jurisdictions or to certain categories of investors.

Options, structured derivative products and futures (including OTC derivatives) are not suitable for all investors. Trading in these instruments is considered risky and may be appropriate only for sophisticated investors. Prior to buying or selling an option, and for the complete risks relating to options, you must receive a copy of "The Characteristics and Risks of Standardized Options." You may read the document at <https://www.theocc.com/publications/risks/riskchap1.jsp> or ask your salesperson for a copy. Various theoretical explanations of the risks associated with these instruments have been published. Supporting documentation for any claims, comparisons, recommendations, statistics or other technical data will be supplied upon request. Past performance is not necessarily indicative of future results. Transaction costs may be significant in option strategies calling for multiple purchases and sales of options, such as spreads and straddles. Because of the importance of tax considerations to many options transactions, the investor considering options should consult with his/her tax advisor as to how taxes affect the outcome of contemplated options transactions.

Mortgage and asset-backed securities may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates or other market conditions. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument referred to in the document. For investment advice, trade execution or other enquiries, clients should contact their local sales representative.

UBS notes that no globally accepted framework or definition (legal, regulatory or otherwise) currently exists, nor is there a market consensus as to what constitutes an "ESG" (Environmental, Social or Governance) or an equivalent-label, or as to what precise attributes are required for the Information (as defined below) to be defined as ESG or equivalently-labelled. Any information, data or other content including from a third party source contained, referred to herein or used for whatsoever purpose by UBS or a third party ("Information"), in relation to any actual or potential ESG objective, issue or consideration is not intended to be relied upon for ESG classification, regulatory regime or industry initiative purposes ("ESG Regimes"). Nothing in these materials is intended to convey, suggest or indicate that UBS considers or represents any product, service, person or body mentioned in these materials as meeting or qualifying for any ESG classification, labelling or similar standards that may exist under the ESG Regimes. UBS has not conducted any assessment of compliance with ESG Regimes. Parties are reminded to make their own assessments for these purposes.

The value of any investment or income may go down as well as up, and investors may not get back the full (or any) amount invested. Past performance is not necessarily a guide to future performance. Neither UBS nor any of its directors, employees or agents accepts any liability for any loss (including investment loss) or damage arising out of the use of all or any of the Information.

Prior to making any investment or financial decisions, any recipient of this document or the information should take steps to understand the risk and return of the investment and seek individualized advice from his or her personal financial, legal, tax and other professional advisors that takes into account all the particular facts and circumstances of his or her investment objectives.

Any prices stated in this document are for information purposes only and do not represent valuations for individual securities or other financial instruments. There is no representation that any transaction can or could have been effected at those prices, and any prices do not necessarily reflect UBS's internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions by UBS or any other source may yield substantially different results.

No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained in any materials to which this document relates (the "Information"), except with respect to Information concerning UBS. The Information is not intended to be a complete statement or summary of the securities, markets or developments referred to in the document. UBS does not undertake to update or keep current the Information. Any statements contained in this report attributed to a third party represent UBS's interpretation of the data, information and/or opinions provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party. In no circumstances

may this document or any of the information (including any forecast, value, index or other calculated amount ("Values")) be used for any of the following purposes:

- (i) valuation or accounting purposes;
- (ii) to determine the amounts due or payable, the price or the value of any financial instrument or financial contract; or
- (iii) to measure the performance of any financial instrument including, without limitation, for the purpose of tracking the return or performance of any Value or of defining the asset allocation of portfolio or of computing performance fees.

By receiving this document and the information you will be deemed to represent and warrant to UBS that you will not use this document or any of the information for any of the above purposes or otherwise rely upon this document or any of the information.

UBS has policies and procedures, which include, without limitation, independence policies and permanent information barriers, that are intended, and upon which UBS relies, to manage potential conflicts of interest and control the flow of information within divisions of UBS and among its subsidiaries, branches and affiliates. For further information on the ways in which UBS Global Research manages conflicts and maintains independence of its research products, historical performance information and certain additional disclosures concerning UBS Global Research recommendations, please visit <https://www.ubs.com/disclosures>.

UBS Global Research will initiate, update and cease coverage solely at the discretion of UBS Global Research Management, which will also have sole discretion on the timing and frequency of any published research product. The analysis contained in this document is based on numerous assumptions. All material information in relation to published research reports, such as valuation methodology, risk statements, underlying assumptions (including sensitivity analysis of those assumptions), ratings history etc. as required by the Market Abuse Regulation, can be found on UBS Neo. Different assumptions could result in materially different results.

The analyst(s) responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting market information. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS into other areas, units, groups or affiliates of UBS. The compensation of the analyst who prepared this document is determined exclusively by UBS Global Research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues; however, compensation may relate to the revenues of UBS and/or its divisions as a whole, of which investment banking, sales and trading are a part, and UBS as a whole.

For financial instruments admitted to trading on an EU regulated market: UBS (excluding UBS Securities LLC) acts as a market maker or liquidity provider (in accordance with the interpretation of these terms under English law or, if not carried out by UBS in the UK the law of the relevant jurisdiction in which UBS determines it carries out the activity) in the financial instruments of the issuer save that where the activity of liquidity provider is carried out in accordance with the definition given to it by the laws and regulations of any other EU jurisdictions, such information is separately disclosed in this document. For financial instruments admitted to trading on a non-EU regulated market: UBS may act as a market maker save that where this activity is carried out in the US in accordance with the definition given to it by the relevant laws and regulations, such activity will be specifically disclosed in this document. UBS may have issued a warrant the value of which is based on one or more of the financial instruments referred to in the document. UBS and its affiliates and employees may have long or short positions, trade as principal and buy and sell in instruments or derivatives identified herein; such transactions or positions may be inconsistent with the opinions expressed in this document.

Within the past 12 months UBS may have received or provided investment services and activities or ancillary services as per MiFID II which may have given rise to a payment or promise of a payment in relation to these services from or to this company.

United Kingdom: This material is distributed by UBS AG, London Branch to persons who are eligible counterparties or professional clients. UBS AG, London Branch is authorised by the Prudential Regulation Authority and subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. **Europe:** Except as otherwise specified herein, these materials are distributed by UBS Europe SE, a subsidiary of UBS AG, to persons who are eligible counterparties or professional clients (as detailed in the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin) Rules and according to MiFID) and are only available to such persons. The information does not apply to, and should not be relied upon by, retail clients. UBS Europe SE is authorised by the European Central Bank (ECB) and regulated by the BaFin and the ECB. **Germany, Luxembourg, the Netherlands, Belgium and Ireland:** Where an analyst of UBS Europe SE has contributed to this document, the document is also deemed to have been prepared by UBS Europe SE. In all cases it is distributed by UBS Europe SE and UBS AG, London Branch. **Turkey:** Distributed by UBS AG, London Branch. No information in this document is provided for the purpose of offering, marketing and sale by any means of any capital market instruments and services in the Republic of Turkey. Therefore, this document may not be considered as an offer made or to be made to residents of the Republic of Turkey. UBS AG, London Branch is not licensed by the Turkish Capital Market Board under the provisions of the Capital Market Law (Law No. 6362). Accordingly, neither this document nor any other offering material related to the instruments/services may be utilized in connection with providing any capital market services to persons within the Republic of Turkey without the prior approval of the Capital Market Board. However, according to article 15 (d) (ii) of the Decree No. 32, there is no restriction on the purchase or sale of the securities abroad by residents of the Republic of Turkey. **Poland:** Distributed by UBS Europe SE (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce. Where an analyst of UBS Europe SE (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce. **Russia:** Prepared and distributed by UBS Bank (OOO). Should not be construed as an individual Investment Recommendation for the purpose of the Russian Law - Federal Law #39-FZ ON THE SECURITIES MARKET Articles 6.1-6.2. **Switzerland:** Distributed by UBS AG to persons who are institutional investors only. UBS AG is regulated by the Swiss Financial Market Supervisory Authority (FINMA). **Italy:** Prepared by UBS Europe SE and distributed by UBS Europe SE and UBS Europe SE, Italy Branch. Where an analyst of UBS Europe SE, Italy Branch has contributed to this document, the document is also deemed to have been prepared by UBS Europe SE, Italy Branch. **France:** Prepared by UBS Europe SE and distributed by UBS Europe SE and UBS Europe SE, France Branch. Where an analyst of UBS Europe SE, France Branch has contributed to this document, the document is also deemed to have been prepared by UBS Europe SE, France Branch. **Spain:** Prepared by UBS Europe SE and distributed by UBS Europe SE and UBS Europe SE, Spain Branch. Where an analyst of UBS Europe SE, Spain Branch has contributed to this document, the document is also deemed to have been prepared by UBS Europe SE, Spain Branch. **Sweden:** Prepared by UBS Europe SE and distributed by UBS Europe SE and UBS Europe SE, Sweden Branch. Where an analyst of UBS Europe SE, Sweden Branch has contributed to this document, the document is also deemed to have been prepared by UBS Europe SE, Sweden Branch. **South Africa:** Distributed by UBS South Africa (Pty) Limited (Registration No. 1995/011140/07), an authorised user of the JSE and an authorised Financial Services Provider (FSP 7328). **Saudi Arabia:** This document has been issued by UBS AG (and/or any of its subsidiaries, branches or affiliates), a public company limited by shares, incorporated in Switzerland with its registered offices at Aeschenvorstadt 1, CH-4051 Basel and Bahnhofstrasse 45, CH-8001 Zurich. This publication has been approved by UBS Saudi Arabia (a subsidiary of UBS AG), a Saudi closed joint stock company incorporated in the Kingdom of Saudi Arabia under commercial register number 1010257812 having its registered office at Tatweer Towers, P.O. Box 75724, Riyadh 11588, Kingdom of Saudi Arabia. UBS Saudi Arabia is authorized and regulated by the Capital Market Authority to conduct securities business under license number 08113-37. **UAE / Dubai:** The information distributed by UBS AG Dubai Branch is only intended for Professional Clients and/or Market Counterparties, as classified under the DFSA rulebook. No other person should act upon this material/communication. The information is not for further distribution within the United Arab Emirates. UBS AG Dubai Branch is regulated by the DFSA in the DIFC. UBS Investment Bank is not licensed to provide banking services in the UAE by the Central Bank of the UAE, nor is it licensed by the UAE Securities and Commodities Authority. **Israel:** This Material is distributed by UBS AG, London Branch. UBS Securities Israel Ltd is a licensed Investment Markete that is supervised by the Israel Securities Authority (ISA). UBS AG, London Branch and its affiliates incorporated outside Israel are not licensed under the Israeli Advisory Law. UBS may engage among others in issuance of Financial Assets or in distribution of Financial Assets of other issuers for fees or other benefits. UBS AG, London Branch and its affiliates may prefer various Financial Assets to which they have or may have an Affiliation (as such term is defined under the Israeli Advisory Law). Nothing in this Material should be considered as investment advice under the Israeli Advisory Law. This Material is being issued only to and/or is directed only at persons who are Eligible Clients within the meaning of the Israeli Advisory Law, and this Material must not be furnished to, relied on or acted upon by any other persons. **United States:** Distributed to US persons by either UBS Securities LLC or by UBS Financial Services Inc., subsidiaries of UBS AG; or by a group, subsidiary or affiliate of UBS AG that is not registered as a US broker-dealer (a "non-US affiliate") to major US institutional investors only. UBS Securities LLC or UBS Financial Services Inc. accepts responsibility for the content of a report prepared by another non-US affiliate when distributed to US persons by UBS Securities LLC or UBS Financial Services Inc. All transactions by a US person in the securities mentioned in this report must be effected through UBS Securities LLC or UBS Financial Services Inc., and not through a non-US affiliate. UBS Securities LLC is not acting as a municipal advisor to any municipal entity or obligated person within the meaning of Section 15B of the Securities Exchange Act (the "Municipal Advisor Rule"), and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of the Municipal Advisor Rule. **Canada:** Distributed by UBS Securities Canada Inc., a registered investment dealer in Canada and a Member-Canadian Investor Protection Fund, or by another affiliate of UBS AG that is registered to conduct business in Canada or is otherwise exempt from registration. **Brazil:** Except as otherwise specified herein, this Material is prepared by UBS Brasil Corretora de Câmbio, Títulos e Valores Mobiliários S.A. (UBS Brasil CCTVM) to persons who are eligible investors residing in Brazil, which are considered to be Professional Investors (Investidores Profissionais), as designated by the applicable regulation, mainly the CVM Resolution No. 30 from the 11th of May 2021 (determines the duty to verify the suitability of products, services and transactions with regards to the client's profile). UBS Brasil CCTVM is a subsidiary of UBS BB Servicos de Assessoria Financeira e Participacoes S.A. ("UBS BB"). UBS BB is an association between UBS AG and Banco do Brasil (through its subsidiary BB – Banco de Investimentos S.A.), of which UBS AG is the majority owner and which provides investment banking services and coverage in Brazil, Argentina, Chile, Paraguay, Peru and Uruguay. UBS Brasil CCTVM is regulated by the Comissão de Valores Mobiliários (CVM) and by the Central Bank of Brazil. Ombudsman: 0800-940-0266/ <https://www.ubs.com/br-pt/ubssb-investment-bank/ombudsman.html>. UBS may hold relevant financial and commercial interest in relation to the company subject to this Research report. **Hong Kong:** Distributed by UBS Securities Asia Limited. Please contact local licensed persons of UBS Securities Asia Limited in respect of any matters arising from, or in connection with, the analysis or document. **Singapore:** Distributed by UBS Securities Pte. Ltd. [Co. Reg. No.: 198500648C] or UBS AG, Singapore Branch. Please contact UBS Securities Pte. Ltd., an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110); or UBS AG, Singapore Branch, an exempt

financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Banking Act (Cap. 19) regulated by the Monetary Authority of Singapore, in respect of any matters arising from, or in connection with, the analysis or document. The recipients of this document represent and warrant that they are accredited and institutional investors as defined in the Securities and Futures Act (Cap. 289). **Japan:** Distributed by UBS Securities Japan Co., Ltd. to professional investors (except as otherwise permitted). Where this report has been prepared by UBS Securities Japan Co., Ltd., UBS Securities Japan Co., Ltd. is the author, publisher and distributor of the report. Distributed by UBS AG, Tokyo Branch to Professional Investors (except as otherwise permitted) in relation to foreign exchange and other banking businesses when relevant. **Australia:** Clients of UBS AG: Distributed by UBS AG (ABN 47 088 129 613 and holder of Australian Financial Services License No. 231087). For all other recipients: Distributed by UBS Securities Australia Ltd (ABN 62 008 586 481 and holder of Australian Financial Services License No. 231098). This document contains general information and/or general advice only and does not constitute personal financial product advice. As such, the Information in this document has been prepared without taking into account any investor's objectives, financial situation or needs, and investors should, before acting on the Information, consider the appropriateness of the Information, having regard to their objectives, financial situation and needs. If the Information contained in this document relates to the acquisition, or potential acquisition of a particular financial product by a 'Retail' client as defined by section 761G of the Corporations Act 2001 where a Product Disclosure Statement would be required, the retail client should obtain and consider the Product Disclosure Statement relating to the product before making any decision about whether to acquire the product. **New Zealand:** Distributed by UBS New Zealand Ltd. UBS New Zealand Ltd is not a registered bank in New Zealand. You are being provided with this publication or material because you have indicated to UBS that you are a "wholesale client" within the meaning of section 5C of the Financial Advisers Act 2008 of New Zealand (Permitted Client). This publication or material is not intended for clients who are not Permitted Clients (non-permitted Clients). If you are a non-permitted Client you must not rely on this publication or material. If despite this warning you nevertheless rely on this publication or material, you hereby (i) acknowledge that you may not rely on the content of this publication or material and that any recommendations or opinions in such this publication or material are not made or provided to you, and (ii) to the maximum extent permitted by law (a) indemnify UBS and its associates or related entities (and their respective Directors, officers, agents and Advisors) (each a 'Relevant Person') for any loss, damage, liability or claim any of them may incur or suffer as a result of, or in connection with, your unauthorised reliance on this publication or material and (b) waive any rights or remedies you may have against any Relevant Person for (or in respect of) any loss, damage, liability or claim you may incur or suffer as a result of, or in connection with, your unauthorised reliance on this publication or material. **Korea:** Distributed in Korea by UBS Securities Pte. Ltd., Seoul Branch. This report may have been edited or contributed to from time to time by affiliates of UBS Securities Pte. Ltd., Seoul Branch. This material is intended for professional/institutional clients only and not for distribution to any retail clients. **Malaysia:** This material is authorized to be distributed in Malaysia by UBS Securities Malaysia Sdn. Bhd (Capital Markets Services License No.: CMSL/A0063/2007). This material is intended for professional/institutional clients only and not for distribution to any retail clients. **India:** Distributed by UBS Securities India Private Ltd. (Corporate Identity Number U67120MH1996PTC097299) 2/F, 3 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai (India) 400051. Phone: +912261556000. It provides brokerage services bearing SEBI Registration Number: INZ000259830; Merchant Banking services bearing SEBI Registration Number: INM000013101; and Research Analyst services bearing SEBI Registration Number: INH000001204. Name of Compliance Officer Mr. Parameshwaran Shivaramakrishnan, Phone : +912261556151, Email : parameshwaran.s@ubs.com, Name of Grievance Officer Parameshwaran Shivaramakrishnan, Phone : +912261556151, Email: ol-ubs-sec-compliance@ubs.com Registration granted by SEBI, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. UBS may have debt holdings or positions in the subject Indian company/companies. UBS may have financial interests (e.g. loan/derivative products, rights to or interests in investments, etc.) in the subject Indian company / companies from time to time. Within the past 12 months, UBS may have received compensation for non-investment banking securities-related services and/or non-securities services from the subject Indian company/companies. The subject company/companies may have been a client/clients of UBS during the 12 months preceding the date of distribution of the research report with respect to investment banking and/or non-investment banking securities-related services and/or non-securities services. With regard to information on associates, please refer to the Annual Report at: https://www.ubs.com/global/en/about_ubs/investor_relations/annualreporting.html **Taiwan:** Except as otherwise specified herein, this material may not be distributed in Taiwan. Information and material on securities/instruments that are traded in a Taiwan organized exchange is deemed to be issued and distributed by UBS Securities Pte. LTD., Taipei Branch, which is licensed and regulated by Taiwan Financial Supervisory Commission. Save for securities/instruments that are traded in a Taiwan organized exchange, this material should not constitute "recommendation" to clients or recipients in Taiwan for the covered companies or any companies mentioned in this document. No portion of the document may be reproduced or quoted by the press or any other person without authorisation from UBS. **Indonesia:** This report is being distributed by PT UBS Sekuritas Indonesia and is delivered by its licensed employee(s), including marketing/sales person, to its client. PT UBS Sekuritas Indonesia, having its registered office at Sequis Tower Level 22 unit 22-1,Jl.Jend. Sudirman, kav.71, SCBD lot 11B, Jakarta 12190. Indonesia, is a subsidiary company of UBS AG and licensed under Capital Market Law no. 8 year 1995, a holder of broker-dealer and underwriter licenses issued by the Capital Market and Financial Institution Supervisory Agency (now Otoritas Jasa Keuangan/OJK). PT UBS Sekuritas Indonesia is also a member of Indonesia Stock Exchange and supervised by Otoritas Jasa Keuangan(OJK). Neither this report nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens except in compliance with applicable Indonesian capital market laws and regulations. This report is not an offer of securities in Indonesia and may not be distributed within the territory of the Republic of Indonesia or to Indonesian citizens in circumstance which constitutes an offering within the meaning of Indonesian capital market laws and regulations.

The disclosures contained in research documents produced by UBS AG, London Branch or UBS Europe SE shall be governed by and construed in accordance with English law.

UBS specifically prohibits the redistribution of this document in whole or in part without the written permission of UBS and in any event UBS accepts no liability whatsoever for any redistribution of this document or its contents or the actions of third parties in this respect. Images may depict objects or elements that are protected by third party copyright, trademarks and other intellectual property rights. © UBS 2025. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.

